Publications by authors named "L Morello"
Chronic Lymphocytic Leukemia (CLL) is the most frequent type of leukemia in Western countries. In recent years, there have been important advances in the knowledge of molecular alterations that underlie the disease's pathogenesis. Very heterogeneous prognostic subgroups have been identified by the mutational status of immunoglobulin heavy variable genes (), FISH analysis and molecular evaluation of mutations.
View Article and Find Full Text PDFArticle Synopsis
- This data descriptor introduces a specialized dataset focused on identifying pathogens like Staphylococcus aureus and Pseudomonas aeruginosa from whole blood samples using advanced mass spectrometry techniques.
- The dataset employs a unique three-tier system, which includes spectral libraries for identifying biomarkers, MS data for optimizing biomarker panels, and PRM data from sepsis patients, achieving 83.3% sensitivity in under seven hours.
- It aims to serve as a vital resource for developing bioinformatic tools and proposing biomarker panels, ultimately enhancing pathogen detection and supporting studies on antimicrobial resistance and epidemiology.
Isatuximab, a novel anti-CD38 monoclonal antibody, is approved in combination with carfilzomib and dexamethasone (Isa-Kd) in relapsed/refractory multiple myeloma (RRMM) patients. Because of its recent introduction, real-world efficacy and safety are poorly reported. In this Italian multicenter real-life observational retrospective study, efficacy and safety of the Isa-Kd regimen were evaluated in a cohort of 103 RRMM patients.
View Article and Find Full Text PDFCOVID-19 laboratory diagnosis primarily relies on molecular tests, highly sensitive during early infection stages with high viral loads. As the disease progresses, sensitivity decreases, requiring antibody detection. Since the beginning of the pandemic, serological tests have been developed and made available in Brazil, but their diagnostic performance varies.
View Article and Find Full Text PDFArticle Synopsis
- Patients with mantle cell lymphoma (MCL) who relapse are split into two groups: early and late progression, based on how long it's been since their diagnosis.
- This study looked at treatment outcomes for 385 late-POD patients treated with two kinds of therapies: Bruton tyrosine kinase inhibitors (BTKi) and chemoimmunotherapy (CIT).
- Findings showed that BTKi treatment led to longer survival without disease progression compared to CIT, suggesting it might be the better choice for these patients.